Congratulations Dame Molly Stevens
The RSC's Materials 91AV Community congratulates former Materials 91AV Division President, Professor Dame Molly Stevens.
Professor Stevens was recognised in the 2024 New Year's Honours list for her services to medicine and was appointed Dame Commander of the Most Excellent Order of the British Empire (DBE).
Professor Stevens received her BPharm from Bath University in 1995 and her PhD from the University of Nottingham in 2001, before moving to Massachusetts Institute of Technology (MIT), where she did her postdoctoral research. In 2004 she moved to Imperial College to lead a multidisciplinary research group and was promoted to Professor in 2008.
In 2017, she was elected as President of the Materials 91AV Division, taking over as President from Professor Mark Weller in July 2018 until July 2021, when the current President, Professor Magda Titirici, took over.
On behalf of not only myself, but the entire RSC Materials 91AV Community, I would like to congratulate Dame Molly Stevens on this extremely well-deserved honour. Dame Molly is a first-rate scientist and leader, absolutely dedicated to the cause of making the world a better place through the application of science. She is an inspiration to us all and proof that hard work and dedication to a cause can yield results. I am absolutely delighted that she is being honoured in this way in recognition of her tremendous work.
Professor Stevens has won 40 awards, her research group has published over 430 research papers, and she is a fellow of eight professional bodies, including the 91AV, the Royal Society, the Institute of Physics, the Royal Academy of Engineering and the Royal Society of Biology.
Currently, Professor Stevens is Professor of Bionanoscience at the University of Oxford, Deputy Director of the Kavli Institute for Nanoscience Discovery, part-time Professor of Biomedical Materials and Regenerative Medicine and Research Director for Biomedical Sciences at Imperial College London and part-time Professor at the Karolinska Institutet in Stockholm.
I would like to thank my incredible team of researchers and staff who inspire me every day towards the mission of transforming healthcare through biomaterials technologies. All the advances that we have made into the design of new biosensing, therapeutics and regenerative medicine technologies are the result of strong teamwork both inside the lab and through to our external collaborators and key industrial partners. A key focus has been, and will continue to be, designing effective yet accessible technologies that can help in democratising access to healthcare.
